380 related articles for article (PubMed ID: 28066928)
21. Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients.
McCulloch R; Lewis D; Crosbie N; Eyre TA; Bolam S; Arasaretnam A; Creasey T; Goradia H; McMillan A; Dawi S; Harrison S; Miles O; Robinson A; Dutton D; Wilson MR; McKay P; Follows G; Phillips N; Patmore R; Lambert J; Bishton M; Osborne W; Johnston R; Kirkwood AA; Rule S
Br J Haematol; 2021 Apr; 193(2):290-298. PubMed ID: 33620106
[TBL] [Abstract][Full Text] [Related]
22. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.
Tam CS; Anderson MA; Pott C; Agarwal R; Handunnetti S; Hicks RJ; Burbury K; Turner G; Di Iulio J; Bressel M; Westerman D; Lade S; Dreyling M; Dawson SJ; Dawson MA; Seymour JF; Roberts AW
N Engl J Med; 2018 Mar; 378(13):1211-1223. PubMed ID: 29590547
[TBL] [Abstract][Full Text] [Related]
23. Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Tappenden P; Simpson E; Hamilton J; Pollard D; Clowes M; Kaltenthaler E; Meiklejohn D; Morley N
Pharmacoeconomics; 2019 Mar; 37(3):333-343. PubMed ID: 30246228
[TBL] [Abstract][Full Text] [Related]
24. A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.
Lee CS; Rattu MA; Kim SS
J Oncol Pharm Pract; 2016 Feb; 22(1):92-104. PubMed ID: 25425007
[TBL] [Abstract][Full Text] [Related]
25. Ibrutinib for mantle cell lymphoma.
Tucker DL; Rule SA
Future Oncol; 2016 Feb; 12(4):477-91. PubMed ID: 26759179
[TBL] [Abstract][Full Text] [Related]
26. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial.
Wang ML; Lee H; Chuang H; Wagner-Bartak N; Hagemeister F; Westin J; Fayad L; Samaniego F; Turturro F; Oki Y; Chen W; Badillo M; Nomie K; DeLa Rosa M; Zhao D; Lam L; Addison A; Zhang H; Young KH; Li S; Santos D; Medeiros LJ; Champlin R; Romaguera J; Zhang L
Lancet Oncol; 2016 Jan; 17(1):48-56. PubMed ID: 26640039
[TBL] [Abstract][Full Text] [Related]
27. Novel therapies for relapsed/refractory mantle cell lymphoma.
Arora PC; Portell CA
Best Pract Res Clin Haematol; 2018 Mar; 31(1):105-113. PubMed ID: 29452660
[TBL] [Abstract][Full Text] [Related]
28. Ibrutinib for the treatment of mantle cell lymphoma.
Herrera AF; Jacobsen ED
Clin Cancer Res; 2014 Nov; 20(21):5365-71. PubMed ID: 25361916
[TBL] [Abstract][Full Text] [Related]
29. Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma.
Goto H; Ito S; Kizaki M; Yamaguchi M; Fukuhara N; Kato K; Saito T; Terui Y; Okubo S; Soshin T; Zeng J; Honda H; Badawi M; Ross JA; Izutsu K
Int J Clin Oncol; 2024 Feb; 29(2):232-240. PubMed ID: 38157190
[TBL] [Abstract][Full Text] [Related]
30. Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.
O'Brien S; Hillmen P; Coutre S; Barr PM; Fraser G; Tedeschi A; Burger JA; Dilhuydy MS; Hess G; Moreno C; Cramer P; Liu E; Chang S; Vermeulen J; Styles L; Howes A; James DF; Patel K; Graef T; Valentino R
Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):648-657.e15. PubMed ID: 30061088
[TBL] [Abstract][Full Text] [Related]
31. Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study.
Epperla N; Zhao Q; Chowdhury SM; Shea L; Moyo TK; Reddy N; Sheets J; Weiner DM; Geethakumari PR; Kandarpa M; Bruno XJ; Thomas C; Churnetski MC; Hsu A; Zurbriggen L; Tan C; Lindsey K; Maakaron J; Caimi PF; Torka P; Bello C; Ayyappan S; Karmali R; Kim SH; Kress A; Kothari S; Sawalha Y; Christian B; David KA; Greenwell IB; Janakiram M; Kenkre VP; Olszewski AJ; Cohen JB; Palmisiano N; Umyarova E; Wilcox RA; Awan FT; Alderuccio JP; Barta SK; Grover NS; Ghosh N; Bartlett NL; Herrera AF; Shouse G
J Hematol Oncol; 2022 Jul; 15(1):96. PubMed ID: 35842643
[TBL] [Abstract][Full Text] [Related]
32. Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study.
Zhang Y; Liu P; Cai J; Jing H; Zou L; Huang H; Wu Y; Li W; Zhong L; Jin X; Ye X; Feng R; Zhang H; Zhang L; Lin L; Sun X; Tian Y; Xia Z; Li Z; Huang H; Xia Y; Cai Q
Cancer Med; 2022 Nov; 11(22):4134-4145. PubMed ID: 35438258
[TBL] [Abstract][Full Text] [Related]
33. Ibrutinib (Imbruvica). Relapsed chronic lymphocytic leukaemia and mantle cell lymphoma: uncertain impact on survival.
January
Prescrire Int; 2016 Apr; 25(170):89-92. PubMed ID: 27183765
[TBL] [Abstract][Full Text] [Related]
34. Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study.
Tivey A; Shotton R; Eyre TA; Lewis D; Stanton L; Allchin R; Walter H; Miall F; Zhao R; Santarsieri A; McCulloch R; Bishton M; Beech A; Willimott V; Fowler N; Bedford C; Goddard J; Protheroe S; Everden A; Tucker D; Wright J; Dukka V; Reeve M; Paneesha S; Prahladan M; Hodson A; Qureshi I; Koppana M; Owen M; Ediriwickrema K; Marr H; Wilson J; Lambert J; Wrench D; Burney C; Knott C; Talbot G; Gibb A; Lord A; Jackson B; Stern S; Sutton T; Webb A; Wilson M; Thomas N; Norman J; Davies E; Lowry L; Maddox J; Phillips N; Crosbie N; Flont M; Nga E; Virchis A; Camacho RG; Swe W; Pillai A; Rees C; Bailey J; Jones S; Smith S; Sharpley F; Hildyard C; Mohamedbhai S; Nicholson T; Moule S; Chaturvedi A; Linton K
Blood Adv; 2024 Mar; 8(5):1209-1219. PubMed ID: 38127279
[TBL] [Abstract][Full Text] [Related]
35. A retrospective analysis of ibrutinib outcomes in relapsed or refractory mantle cell lymphoma.
Lee YP; Jung YJ; Cho J; Ko YH; Kim WS; Kim SJ; Yoon SE
Blood Res; 2023 Dec; 58(4):208-220. PubMed ID: 38151961
[TBL] [Abstract][Full Text] [Related]
36. Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus.
Hess G; Rule S; Jurczak W; Jerkeman M; Santucci Silva R; Rusconi C; Caballero D; Joao C; Witzens-Harig M; Bence-Bruckler I; Cho SG; Zhou W; Goldberg JD; Trambitas C; Enny C; Vermeulen J; Traina S; Chiou CF; Diels J; Dreyling M
Leuk Lymphoma; 2017 Dec; 58(12):2824-2832. PubMed ID: 28556689
[TBL] [Abstract][Full Text] [Related]
37. A phase I study of carfilzomib in combination with ibrutinib for relapsed refractory mantle cell lymphoma.
Lee HJ; Schmelz JL; Cramer F; Romaguera JE; Badillo M; Wang M
Br J Haematol; 2020 Mar; 188(6):e94-e98. PubMed ID: 32057090
[No Abstract] [Full Text] [Related]
38. Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia.
Kim ES; Dhillon S
Drugs; 2015 May; 75(7):769-76. PubMed ID: 25802231
[TBL] [Abstract][Full Text] [Related]
39. Combining Ibrutinib with Chk1 Inhibitors Synergistically Targets Mantle Cell Lymphoma Cell Lines.
Restelli V; Lupi M; Vagni M; Chilà R; Bertoni F; Damia G; Carrassa L
Target Oncol; 2018 Apr; 13(2):235-245. PubMed ID: 29441438
[TBL] [Abstract][Full Text] [Related]
40. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.
Wang ML; Blum KA; Martin P; Goy A; Auer R; Kahl BS; Jurczak W; Advani RH; Romaguera JE; Williams ME; Barrientos JC; Chmielowska E; Radford J; Stilgenbauer S; Dreyling M; Jedrzejczak WW; Johnson P; Spurgeon SE; Zhang L; Baher L; Cheng M; Lee D; Beaupre DM; Rule S
Blood; 2015 Aug; 126(6):739-45. PubMed ID: 26059948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
